Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STUNNIN: SBRT ± short-term androgen deprivation for unfavorable intermediate/high-risk prostate cancer
2024-511886-12-00Phase 2Authorised
- Sponsor
- Istituti Fisioterapici Ospitalieri
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of bicalutamide in prostate adenocarcinoma (2 arms), sponsored by Istituti Fisioterapici Ospitalieri. Primary endpoint: 3-year biochemical no evidence of disease (bNED) survival. Planned start Apr 2024; status: authorised.
02
Drugs
bicalutamide
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on 2024-511886-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511886-12-00.